Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy
Background - Current guidelines suggest that all cancer patients with venous thrombosis be treated with long-term low molecular weight heparin. Whether treatment strategies should vary according to clinical characteristics remains unknown. // Systematic review - A systematic review was performed to...
Main Author: | Louzada, Martha |
---|---|
Other Authors: | Wells, Philip |
Language: | en |
Published: |
Université d'Ottawa / University of Ottawa
2011
|
Subjects: | |
Online Access: | http://hdl.handle.net/10393/19827 http://dx.doi.org/10.20381/ruor-4465 |
Similar Items
-
Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy
by: Louzada, Martha
Published: (2011) -
Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy
by: Louzada, Martha
Published: (2011) -
Evaluating Risk of Recurrent Venous Thromboembolism During the Anticoagulation Period in Patients with Malignancy
by: Louzada, Martha
Published: (2011) -
Risk factors for Venous thromboembolism and duration of anticoagulation therapy
by: Antonijević Nebojša M., et al.
Published: (2013-01-01) -
Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
by: Jeffrey I. Weitz, et al.
Published: (2020-10-01)